Seelos Therapeutics, Inc

(NASDAQ:SEEL)

Latest On Seelos Therapeutics, Inc (SEEL):

Date/Time Type Description Signal Details
2023-05-15 14:35 ESTNewsSeelos Therapeutics GAAP EPS of -$0.12 misses by $0.02, revenue of $0.81MN/A
2023-03-10 13:11 ESTNewsSeelos stock falls on ~$11.2M stock, warrants direct offeringN/A
2023-02-12 08:37 ESTNewsPsychedelic Sunday: Scrutinizing Psychedelic StocksN/A
2023-01-08 20:10 ESTNewsScrutinizing Psychedelic StocksN/A
2022-12-16 09:18 ESTNewsSeelos drops 14% after pre-clinical data for Parkinson's disease candidateN/A
2022-10-04 21:07 ESTNewsSeelos: Data This Year Is CriticalN/A
2022-08-24 09:27 ESTNewsSeelos wins Parkinson’s research grant for gene therapy programN/A
2022-06-10 02:56 ESTNewsSeelos shares data supporting dementia studies for Parkinson’s candidateN/A
2022-05-18 13:02 ESTNewsSeelos Therapeutics to get US patent for SLS-007 linked to treating neurodegenerative diseasesN/A
2022-03-08 19:21 ESTNewsSeelos gets acknowledgement letter from Australian regulator for Alzheimer's studyN/A
2021-12-22 23:42 ESTNewsSeelos: FDA Action Makes It Highly AttractiveN/A
2021-12-06 21:52 ESTNewsSeelos Therapeutics secures composition of matter patent in Japan for SLS-007N/A
2021-11-25 03:55 ESTNewsSeelos Therapeutics raises $20M in senior convertible notes offeringN/A
2021-11-25 03:55 ESTNewsSeelos Therapeutics jumps 9% on acquisition of license for sublingual ketamine wafersN/A
2021-11-15 12:14 ESTNewsWarning: SEEL is at high risk of performing badlyN/A
2021-10-15 20:15 ESTNewsDEA calls for increase in production of psychedelics for research - Marijuana MomentN/A
2021-10-01 21:01 ESTNewsSeelos Therapeutics: Shares Have Finally Found A Floor But Risk RemainsN/A
2021-09-29 22:55 ESTNewsSeelos Therapeutics cools off day after Roth upgrade led to 14% riseN/A
2021-09-28 01:20 ESTNewsSeelos climbs after Roth Capital upgraded with over threefold rise in price targetN/A
2021-09-01 10:12 ESTNewsSeelos Therapeutics picks internal candidates for CFO and communications chiefN/A
2021-07-21 23:50 ESTNewsSeelos Therapeutics' SLS-005 an Orphan Drug in Europe for amyotrophic lateral sclerosisN/A
2021-07-21 23:47 ESTNewsStryker 'premium growth' prompts upgrade, UHC undervalued by 10% and more in analyst actionN/A
2021-07-21 23:40 ESTNewsSeelos: Superior Data, But Early StageN/A
2021-07-21 23:22 ESTNewsSeelos Therapeutics makes it to the Russell 2000, Russell 3000 and Russell Microcap IndexesN/A
2021-07-21 23:16 ESTNewsVertex initiated at Raymond James, Altimmune price target lowered, and more in analyst actionN/A
2021-07-21 23:13 ESTNewsSeelos doses first patient in part 2 of SLS-002 major depressive disorder studyN/A
2021-07-21 23:11 ESTNewsSeelos Therapeutics posts promising data from SLS-004 rodent studyN/A
2021-07-21 22:56 ESTNewsInterest in "shroom stocks" rises as investors see potential of psychedelics as therapyN/A
2021-04-07 21:09 ESTNewsSeelos Therapeutics shares 6% higher as BTIG reiterates buy following Aptar dealN/A
2021-04-06 08:39 ESTNewsSeelos partners with AptarGroup for drug delivery systemN/A
2021-03-30 12:24 ESTNewsAscendis downgraded at Oppenheimer, Aytu initiated at overweight at Cantor and more in today's analyst actionN/A
2021-03-16 21:59 ESTFinancialsCompany financials have been released.Neutral
2021-03-16 21:59 ESTEarnings EstimateAn EPS average of -$0.44 is estimated for the 2022 year.Sell
2021-03-16 21:59 ESTEarnings EstimateAn EPS average of -$0.07 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-16 21:59 ESTAnalyst RatingThe Analyst Target Price has increased from $9 to $10.67.Buy
2021-03-12 10:50 ESTNewsSeelos surges as BTIG initiates with Street high targetN/A
2021-03-12 08:30 ESTFinancialsCompany financials have been released.Neutral
2021-03-11 13:48 ESTNewsSeelos Therapeutics: SLS-002 For Suicidality Is Very PromisingN/A
2021-03-10 12:16 ESTAnalyst RatingThe Analyst Target Price has increased from $8 to $9.Buy
2021-03-06 01:56 ESTNewsSeelos completes enrollment in part 1 of SLS-002 suicidal ideation studyN/A
2021-02-18 21:53 ESTNewsSeelos amends the agreement with Vyera PharmaceuticalsN/A
2021-01-29 23:28 ESTNewsSeelos announces issuance of a patent for trehalose (SLS-005) in AustraliaN/A
2021-01-26 13:08 ESTNewsSeelos Therapeutics to raise ~$31M capital in stock offeringN/A
2021-01-22 19:45 ESTNewsSeelos perks up after Japanese patent for SLS-005N/A
2021-01-15 15:17 ESTNewsSeelos Therapeutics' patient dosing in SLS-002 study gets underwayN/A
2021-01-06 10:27 ESTNewsSeelos' expects to commence SLS-005 study in rare neurological disease in H1 2021, shares up 6%N/A
2020-12-22 08:22 ESTNewsSeelos nabs new patent in Israel covering trehaloseN/A
2020-12-21 14:39 ESTNewsSeelos Therapeutics' trehalose nabs Israel patentN/A
2020-12-16 11:36 ESTNewsSeelos Therapeutics (SEEL) files for $200M mixed shelf, shares down 8%N/A
2020-12-15 00:43 ESTNewsSeelos raises $10M via convertible debt offeringN/A

About Seelos Therapeutics, Inc (SEEL):

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

SEEL Quotes by TradingView

See Advanced Chart

General

  • Name Seelos Therapeutics, Inc
  • Symbol SEEL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 9
  • Last Split Factor1:30
  • Last Split Date2019-01-24
  • Fiscal Year EndDecember
  • IPO Date1999-04-19
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Web URLhttp://seelostherapeutics.com
View More

Valuation

  • Trailing PE 0.78
  • Price/Sales (Trailing 12 Mt.) 431.84
  • Price/Book (Most Recent Quarter) 32.74
  • Enterprise Value Revenue 563.13
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.38
  • Next Year EPS Estimate -$0.44
  • Next Quarter EPS Estimate -$0.07
  • Return on Assets -82%
  • Return on Equity -1489%
  • Earnings Per Share -$0.81
  • Revenue Per Share $0
  • Gross Profit -10984000
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 303.62 million
  • Analyst Target Price $10.67
  • Book Value Per Share $0.05
View More

Share Statistics

  • Shares Outstanding 73.25 million
  • Shares Float 68.1 million
  • % Held by Insiders 1338%
  • % Held by Institutions 10.09%
  • Shares Short 2.58 million
  • Shares Short Prior Month 2.44 million
  • Short Ratio 0.56
  • Short % of Float 4%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 2.81
  • 52 Week High $4.92
  • 52 Week Low $0.42
  • 50 Day Moving Average 3.25
  • 200 Day Moving Average 1.63
View More

Dividends

  • Dividend Date 2019-01-24
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Seelos Therapeutics, Inc (SEEL) Dividend Calendar:

SEEL's last dividend payment was made to shareholders on January 24, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Seelos Therapeutics, Inc (SEEL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$N/A-$0.13-$0.08-56.06%
2020-09-302020-11-12$N/A-$0.09-$0.08-12.5%
2020-06-302020-08-14$N/A-$0.08-$0.1440.74%
2020-03-312020-05-07$N/A-$0.14-$0.2236.36%
2019-12-312020-03-17$N/A-$0.27-$0.17-63.64%
2019-09-302019-11-07$375000-$0.15-$0.12-25.42%
2019-06-302019-08-01$N/A-$0.16-$0.15-7.13%
2019-03-312019-05-21$N/A-$1.38-$0.20-590.45%
2018-12-312019-03-28$N/A-$1.97
2018-09-302018-10-31$N/A-$3.58
2018-06-302018-08-09$N/A-$3.00-$3.6016.67%
2018-03-312018-05-03$N/A-$4.20-$3.60-16.67%
2017-12-312018-03-01$N/A-$4.20-$4.353.45%
2017-09-302017-11-02$N/A-$9.00-$4.65-93.55%
2017-06-302017-08-02$N/A-$4.50-$4.806.25%
2017-03-312017-05-11$N/A-$13.20$37.35-135.34%
2016-12-312017-03-13$356000$0.03-$0.14121.43%
2016-09-302016-11-08$4.32 million-$0.19-$0.6068.33%
2016-06-302016-08-04$464000-$0.50-$0.8037.5%
2016-03-312016-05-09-$0.50-$0.8742.53%
2015-12-312016-03-09$2.63 million-$0.50-$1.1054.55%
2015-09-302015-11-05$1.27 million-$1.00-$1.109.09%
2015-06-302015-08-05$462000-$1.00-$1.2520%
2015-03-312015-05-11$475000-$1.30-$1.00-30%
2014-12-312015-03-16$1.91 million-$0.90-$1.2025%
2014-09-302014-11-10$1.9 million-$0.80-$0.9717.53%
2014-06-302014-08-11$5.45 million$9.00-$11.00181.82%
2014-03-312014-05-12$N/A-$27.00-$9.00-200%
2013-12-312014-03-17-$12.00-$17.0029.41%
2013-09-302013-11-08$28000-$24.00-$33.0027.27%
2013-06-302013-08-14$1.19 million-$42.00-$32.00-31.25%
2013-03-312013-05-10$1.02 million-$69.00-$39.00-76.92%
2012-12-312013-03-18$2.36 million-$75.00-$55.00-36.36%
2012-09-302012-11-08$5.15 million-$27.00-$22.50-20%
2012-06-302012-08-09$119633-$57.00-$29.25-94.87%
2012-03-312012-05-10$781481-$58.88
2011-12-312012-03-13-$66.00-$6.00-1000%
2011-09-302011-11-14$799419-$32.97
2011-06-302011-08-15$1.6 million-$117.99
2011-03-312011-05-13-$53.46
2010-12-312011-03-10-$222.00-$36.00-516.67%
2010-09-302010-11-09-$61.29
2010-06-302010-08-12-$140.43
2010-03-312010-05-13-$375.57
2009-12-312010-03-24-$1,530.02
2009-09-302009-11-10-$60.39
2009-06-302009-08-10-$75.64
2009-03-312009-05-11$36.52
2008-12-312009-03-16$61.29
2008-09-302008-11-10-$162.99
2008-06-302008-08-06-$90.00-$90.000%
2008-03-312008-05-12-$90.00-$135.0033.33%
2007-12-312008-03-12-$135.00-$67.50-100%
2007-09-302007-11-14-$90.00-$90.000%
2007-06-302007-08-14-$90.00-$90.000%
2007-03-312007-05-10-$135.00-$135.000%
2006-12-312007-03-26-$135.00-$90.00-50%
2006-09-302006-11-09-$135.00-$90.00-50%
2006-06-302006-08-09-$90.00-$90.000%
2006-03-312006-05-09-$225.00-$180.00-25%
2005-12-312006-03-17-$270.00-$225.00-20%
2005-09-302005-11-09-$315.00-$360.0012.5%
2005-06-302005-08-09-$450.00-$472.504.76%
2005-03-312005-05-10-$402.53
2004-12-312005-03-03-$405.00
2004-09-302004-11-08-$461.60
2004-06-302004-08-06-$443.05
2004-03-312004-05-06-$445.56
2003-12-312004-03-04-$886.37
2003-09-302003-11-12-$396.20
2003-06-302003-08-12-$1,067.26
2003-03-312003-03-31-$543.16
2002-09-302002-09-30-$1,095.36
2002-06-302002-08-14-$1,215.00-$900.00-35%
2002-03-312002-05-14-$990.00-$1,035.004.35%
2001-12-312002-03-29-$1,035.00-$585.00-76.92%
2001-09-302001-11-14-$630.00-$675.006.67%
2001-06-302001-08-13-$630.00-$585.00-7.69%
2001-03-312001-05-14-$585.00-$1,305.0055.17%
2000-12-312001-03-01-$630.00-$2,767.5077.24%
2000-09-302000-11-10-$360.00-$765.0052.94%
2000-06-302000-06-30-$598.32
2000-03-312000-03-31-$295.93
1999-09-301999-09-30-$304.83
1999-06-301999-06-30-$479.19
1999-03-311999-03-31-$411.79
1998-09-301998-09-30-$705.66
1998-06-301998-06-30-$741.69
1998-03-311998-03-31-$724.67

Seelos Therapeutics, Inc (SEEL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Seelos Therapeutics, Inc (SEEL) Chart:

Seelos Therapeutics, Inc (SEEL) News:

Below you will find a list of latest news for Seelos Therapeutics, Inc (SEEL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Seelos Therapeutics, Inc (SEEL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-1710.05CALL50 00FALSE00
2024-05-1720.05CALL0 10FALSE00
2024-05-1730CALL0 00FALSE00
2024-05-1740CALL0 00FALSE00
2024-05-1710.81PUT1 210TRUE00
2024-05-1721.8PUT1 00TRUE00
2024-05-1732.75PUT0 00TRUE00
2024-05-1740PUT0 10TRUE00

Latest SEEL Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST34$0.6944
Jun 13, 2022 7:59 PM EST38$0.6944
Jun 13, 2022 7:59 PM EST2$0.6944
Jun 13, 2022 7:59 PM EST5$0.6944
Jun 13, 2022 7:59 PM EST11$0.6944

Seelos Therapeutics, Inc (SEEL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000138/0001136261-20-000138-index.htm
2019-02-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1017491/000000000019001794/0000000000-19-001794-index.htm
2019-02-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1017491/000000000019001795/0000000000-19-001795-index.htm
2019-12-03UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1017491/000000000019016033/0000000000-19-016033-index.htm
2020-01-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1017491/000000000020000681/0000000000-20-000681-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000089924318029911/0000899243-18-029911-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000089924318029913/0000899243-18-029913-index.htm
2019-01-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000089924319001840/0000899243-19-001840-index.htm
2019-01-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000089924319001841/0000899243-19-001841-index.htm
2019-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1017491/000091957419001799/0000919574-19-001799-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1017491/000091957420001527/0000919574-20-001527-index.htm
2020-01-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1017491/000092963820000060/0000929638-20-000060-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1017491/000093041319000513/0000930413-19-000513-index.htm
2018-10-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000101749118000104/0001017491-18-000104-index.htm
2018-11-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000101749118000108/0001017491-18-000108-index.htm
2018-11-16425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1017491/000101749118000109/0001017491-18-000109-index.htm
2018-11-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1017491/000101749118000110/0001017491-18-000110-index.htm
2019-08-30DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000101749119000002/0001017491-19-000002-index.htm
2020-09-14DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000101749120000001/0001017491-20-000001-index.htm
2019-03-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1017491/000110465919013756/0001104659-19-013756-index.htm
2020-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1017491/000110465920013413/0001104659-20-013413-index.htm
2019-01-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000010/0001136261-19-000010-index.htm
2019-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000011/0001136261-19-000011-index.htm
2019-01-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000012/0001136261-19-000012-index.htm
2019-01-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000013/0001136261-19-000013-index.htm
2019-01-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000014/0001136261-19-000014-index.htm
2019-01-308-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000017/0001136261-19-000017-index.htm
2019-01-31SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000019/0001136261-19-000019-index.htm
2019-02-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1017491/000113626119000033/0001136261-19-000033-index.htm
2019-02-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1017491/000113626119000034/0001136261-19-000034-index.htm
2019-02-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000038/0001136261-19-000038-index.htm
2019-02-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000044/0001136261-19-000044-index.htm
2019-02-13424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1017491/000113626119000061/0001136261-19-000061-index.htm
2019-02-13424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1017491/000113626119000062/0001136261-19-000062-index.htm
2019-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000068/0001136261-19-000068-index.htm
2019-02-25S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000081/0001136261-19-000081-index.htm
2019-03-018-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000089/0001136261-19-000089-index.htm
2019-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000099/0001136261-19-000099-index.htm
2019-03-08424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1017491/000113626119000100/0001136261-19-000100-index.htm
2019-03-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000107/0001136261-19-000107-index.htm
2019-03-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000108/0001136261-19-000108-index.htm
2019-03-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000109/0001136261-19-000109-index.htm
2019-03-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000110/0001136261-19-000110-index.htm
2019-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000116/0001136261-19-000116-index.htm
2019-03-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1017491/000113626119000121/0001136261-19-000121-index.htm
2019-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000126/0001136261-19-000126-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000152/0001136261-19-000152-index.htm
2019-05-15NT 10-QNotification of inability to timely file Form 10-Q or 10-QSBhttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000157/0001136261-19-000157-index.htm
2019-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000163/0001136261-19-000163-index.htm
2019-05-2110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1017491/000113626119000166/0001136261-19-000166-index.htm
2019-06-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1017491/000113626119000177/0001136261-19-000177-index.htm
2019-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000178/0001136261-19-000178-index.htm
2019-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000181/0001136261-19-000181-index.htm
2019-07-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000192/0001136261-19-000192-index.htm
2019-08-0110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1017491/000113626119000209/0001136261-19-000209-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000215/0001136261-19-000215-index.htm
2019-08-15S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000220/0001136261-19-000220-index.htm
2019-08-23424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1017491/000113626119000225/0001136261-19-000225-index.htm
2019-08-26424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1017491/000113626119000228/0001136261-19-000228-index.htm
2019-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000232/0001136261-19-000232-index.htm
2019-10-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000239/0001136261-19-000239-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1017491/000113626119000264/0001136261-19-000264-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000265/0001136261-19-000265-index.htm
2019-11-21S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1017491/000113626119000270/0001136261-19-000270-index.htm
2019-11-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1017491/000113626119000274/0001136261-19-000274-index.htm
2019-12-02424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1017491/000113626119000276/0001136261-19-000276-index.htm
2020-01-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1017491/000113626120000006/0001136261-20-000006-index.htm
2020-01-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000007/0001136261-20-000007-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000008/0001136261-20-000008-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000009/0001136261-20-000009-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000010/0001136261-20-000010-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000011/0001136261-20-000011-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000012/0001136261-20-000012-index.htm
2020-01-22S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1017491/000113626120000020/0001136261-20-000020-index.htm
2020-01-30S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1017491/000113626120000026/0001136261-20-000026-index.htm
2020-01-30FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000027/0001136261-20-000027-index.htm
2020-02-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000031/0001136261-20-000031-index.htm
2020-02-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000032/0001136261-20-000032-index.htm
2020-02-05S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1017491/000113626120000037/0001136261-20-000037-index.htm
2020-02-07S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1017491/000113626120000041/0001136261-20-000041-index.htm
2020-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000042/0001136261-20-000042-index.htm
2020-02-11424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1017491/000113626120000045/0001136261-20-000045-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000050/0001136261-20-000050-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000053/0001136261-20-000053-index.htm
2020-03-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1017491/000113626120000077/0001136261-20-000077-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000084/0001136261-20-000084-index.htm
2020-03-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1017491/000113626120000085/0001136261-20-000085-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000088/0001136261-20-000088-index.htm
2020-03-1710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1017491/000113626120000092/0001136261-20-000092-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000095/0001136261-20-000095-index.htm
2020-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000098/0001136261-20-000098-index.htm
2020-04-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000103/0001136261-20-000103-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1017491/000113626120000114/0001136261-20-000114-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000118/0001136261-20-000118-index.htm
2020-05-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000119/0001136261-20-000119-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000120/0001136261-20-000120-index.htm
2020-05-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000124/0001136261-20-000124-index.htm
2020-05-218-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000131/0001136261-20-000131-index.htm
2020-05-21S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000135/0001136261-20-000135-index.htm
2020-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000137/0001136261-20-000137-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000138/0001136261-20-000138-index.htm
2020-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1017491/000113626120000156/0001136261-20-000156-index.htm
2020-09-08424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1017491/000113626120000162/0001136261-20-000162-index.htm
2020-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000113626120000167/0001136261-20-000167-index.htm
2018-11-16S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1017491/000114036118043294/0001140361-18-043294-index.htm
2018-11-20424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1017491/000114036118043477/0001140361-18-043477-index.htm
2018-11-30425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1017491/000114036118044178/0001140361-18-044178-index.htm
2018-12-06425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1017491/000114036118044631/0001140361-18-044631-index.htm
2018-12-26425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1017491/000114036118045831/0001140361-18-045831-index.htm
2019-01-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000114036119000397/0001140361-19-000397-index.htm
2019-01-04425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1017491/000114036119000398/0001140361-19-000398-index.htm
2019-01-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000114036119001204/0001140361-19-001204-index.htm
2019-01-16425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1017491/000114036119001205/0001140361-19-001205-index.htm
2019-01-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/0001140361-19-001465-index.htm
2019-01-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000114036119001467/0001140361-19-001467-index.htm
2019-04-12DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1017491/000114036119007041/0001140361-19-007041-index.htm
2020-04-01PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1017491/000114036120007717/0001140361-20-007717-index.htm
2020-04-13DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1017491/000114036120008730/0001140361-20-008730-index.htm
2020-05-04DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1017491/000114036120010609/0001140361-20-010609-index.htm
2018-12-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1017491/000119312518349990/0001193125-18-349990-index.htm
2018-12-14425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1017491/000119312518349992/0001193125-18-349992-index.htm
2018-12-17425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1017491/000119312518350191/0001193125-18-350191-index.htm
2018-12-17425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1017491/000119312518350192/0001193125-18-350192-index.htm
2018-12-17425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1017491/000119312518350194/0001193125-18-350194-index.htm
2019-04-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1017491/000119312519106750/0001193125-19-106750-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1017491/000119312520033195/0001193125-20-033195-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1017491/000138713119000996/0001387131-19-000996-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1017491/000138713120001629/0001387131-20-001629-index.htm
2019-01-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1017491/000153561019000023/0001535610-19-000023-index.htm
2018-11-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1017491/999999999518002940/9999999995-18-002940-index.htm
2019-02-13EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1017491/999999999519000237/9999999995-19-000237-index.htm
2019-02-13EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1017491/999999999519000238/9999999995-19-000238-index.htm
2019-12-02EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1017491/999999999519002729/9999999995-19-002729-index.htm
2020-02-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1017491/999999999520000318/9999999995-20-000318-index.htm
2018-11-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1017491/999999999718009096/9999999997-18-009096-index.htm
2020-03-06CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1017491/999999999720001139/9999999997-20-001139-index.htm
2020-09-18CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1017491/999999999720004692/9999999997-20-004692-index.htm

Seelos Therapeutics, Inc (SEEL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Seelos Therapeutics, Inc (SEEL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1338%
Institutional Ownership: 1009%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-01-24Raj MehraOfficerBuy3,081,546.003,081,546.00https://www.sec.gov/Archives/edgar/data/1017491/000113626119000011/0001136261-19-000011-index.htm
2020-02-13Raj MehraOfficerBuy133,333.000.7599,999.753,214,879.00https://www.sec.gov/Archives/edgar/data/1017491/000113626120000053/0001136261-20-000053-index.htm